Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia (SILDI-SAFE)

  • STATUS
    Recruiting
  • End date
    Dec 8, 2023
  • participants needed
    120
  • sponsor
    Christoph P Hornik, MD MPH
Updated on 8 July 2022

Summary

This is a multicenter, randomized, placebo-controlled, sequential dose-escalating, double-masked, safety study of sildenafil in premature infants (inpatient in Neonatal Intensive Care Units (NICUs)) with severe bronchopulmonary dysplasia (BPD).

Description

Screening/Baseline

Research staff will document informed consent from the parent/guardian for all participants who satisfy eligibility criteria. The following information will be recorded in the case report form (eCRF) from the clinical medical record:

  1. Participant demographics, including birth weight and gestational age at birth
  2. Maternal race/ethnicity
  3. Medical history
  4. Physical examination, including actual weight
  5. All mean arterial pressure (MAP) obtained in the 24 hours before the first dose
  6. Concomitant medications (within 24 hours prior to start of study drug)
  7. Respiratory assessment
  8. Laboratory evaluations
  9. Echocardiogram: If performed per local standard of care < 14 days prior to start of study drug, a study-specific echocardiogram need not be repeated. If not performed per local standard of care < 14 days prior to start of study drug, an echocardiogram will be required to confirm eligibility.
  10. Cardiac catheterization reports, if performed per local standard of care < 14 days prior to start of study drug.
  11. Adverse events following initial study-specific procedure

Treatment Period

The treatment period will include Days 1-28 or last day of study drug if early withdrawal of study drug. The following information will be collected and recorded while the participant is on study drug:

  1. Actual weight on study Days 7 (± 1 day), 14 (± 1 day), 21 (± 1 day), and 28 (± 1 day) of study drug administration
  2. Date, time, amount, and route of study drug dose
  3. All concomitant medications
  4. MAP
  5. All MAP values obtained 24 hours after the first dose of study drug regardless of administration route.
  6. MAP values will be obtained at a minimum at the following time points i. Prior to the first dose of study drug or dose escalation: 2 hours (± 5 minutes), 1 hour (± 5 minutes), and 15 minutes (± 5 minutes) ii. If administration route is IV:
  7. During and following the first dose of study drug or dose escalation: MAP at start of infusion, every 15 minutes (± 5 minutes) during infusion, at end of infusion (inclusive of flush) (± 5 minutes), at 15 and 30 minutes (± 5 minutes) after end of infusion, hourly (± 15 minutes) for 4 hours, and once in the remaining 2 hours prior to the next dose.
  8. For subsequent IV doses, the lowest valid MAP value should be recorded daily while on study drug.

iii. If the administration route is enteral:

  1. During and following the first dose of study drug or dose escalation: MAP at start of enteral administration, then every 15 minutes (± 5 minutes) for 90 minutes (1.5 hours), then every 30 minutes (± 5 minutes) for 60 minutes (1 hour), then hourly (± 15 minutes) for 4 hours, then once in the remaining 2 hours prior to the next dose.
  2. For subsequent enteral doses, the lowest valid MAP value should be recorded daily while on study drug.
  3. Respiratory assessment, weekly
  4. Laboratory evaluations, at least every other week
  5. Echocardiograms and cardiac catheterization reports, if performed per local standard of care
  6. Pharmacokinetic (PK) sampling (after Day 7)
  7. Adverse events

Weaning Period (Cohorts 2 and 3)

The weaning period will begin following Day 28 of study drug or, following the last day of study drug if participant was withdrawn from study drug prior to Day 28 and the dose escalated to ≥ 0.5 mg/kg IV or ≥ 1 mg/kg enteral.

The following information will be collected and recorded while the participant is weaning from study drug:

  1. Date, time, amount and route of study drug dose
  2. MAP (the lowest MAP value on last day of wean should be recorded).
  3. Respiratory assessment on last day of wean
  4. Echocardiogram and cardiac catheterization reports, if performed per local standard of care
  5. Adverse events

Follow-up Period

The follow-up period will include Days 1-28 after the last study drug dose; last study drug dose may occur prior to Day 28 for those participants who withdraw from study drug early; on Day 28 for those participants who complete the full treatment period; or after last weaning dose for those participants who require weaning. The following information will be reported in electronic data capture system (EDC) at Day 1 (+ 2 days) and 14 (± 2days) of the follow-up period (or days closest to and after Day 1 and 14, if >1 assessment is available), except for MAP, adverse events (AEs), and serious adverse events (SAEs) (which will be reported from Days 1-28 post last study drug dose) and standard of care echocardiograms or cardiac catheterization reports:

  1. Physical examination, including actual weight
  2. MAP (the lowest valid MAP value on follow-up Day 1, 14, 21, and 28 should be recorded).
  3. Respiratory assessment
  4. Laboratory evaluations
  5. Echocardiogram on follow-up Day 1 (+2 days). If performed per local standard of care, a study-specific echocardiogram need not be repeated. If not performed per local standard of care on Day 1 (+2 days) of the follow-up period, an echocardiogram will need to be performed.
  6. Echocardiograms and cardiac catheterization reports, if performed per local standard of care (during follow-up Days 1-28)
  7. Adverse events and SAEs (during follow-up Days 1-28)

Final Study Assessment

Final study assessment will occur at the time of discharge or transfer. The following information will be collected:

  1. Physical examination, including actual weight
  2. Respiratory assessment
  3. Echocardiogram and cardiac catheterization reports, if performed per local standard of care on the day of discharge or transfer or up to 2 days prior.
  4. Global rank
  5. Discharge information A. Discharge or transfer B. Death C. Duration of hospitalization
  6. Record if treatment for retinopathy of prematurity (ROP) was required

Details
Condition Bronchopulmonary Dysplasia of Newborn
Treatment Placebo, Sildenafil
Clinical Study IdentifierNCT04447989
SponsorChristoph P Hornik, MD MPH
Last Modified on8 July 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Documented informed consent from parent or guardian, prior to study procedures
< 29 weeks gestational age at birth
32-44 weeks postmenstrual age
Receiving respiratory support at enrollment
If 32 0/7-35 6/7 weeks postmenstrual age: mechanical ventilation (high frequency or conventional)
If 36 0/7-44 6/7 weeks postmenstrual age: mechanical ventilation (high frequency or conventional) OR continuous positive airway pressure (CPAP)
Note
CPAP is defined as any of the following
Criteria 3 and 4 define severe BPD for the purposes of this study
Nasal cannula > 2 liters per minute (LPM)
Nasal continuous positive airway pressure (NCPAP)
Nasal intermittent positive pressure ventilation (NIPPV)
Noninvasive neurally adjusted ventilatory assist (NAVA)
Any other device designed to provide positive pressure through a nasal device (e.g., RAM cannula, etc.)

Exclusion Criteria

Previous enrollment and dosing in this study, protocol number (NHLBI-2019-SIL), "Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia (BPD)
Previous exposure to sildenafil within 7 days prior to randomization
Previous exposure to vasopressors within 24 hours prior to randomization
Previous exposure to inhaled nitric oxide within 24 hours prior to randomization
Evidence of pulmonary hypertension or moderate/large patent ductus arteriosus (PDA) on the most recent echocardiogram performed within 14 days prior to randomization
Known major congenital heart defect requiring medical or surgical intervention in the neonatal period
Previous exposure to milrinone within 24 hours prior to randomization
Known allergy to sildenafil
Known sickle cell disease
Aspartate aminotransferase (AST) > 225 U/L < 72 hours prior to randomization
Alanine aminotransferase (ALT) > 150 U/L < 72 hours prior to randomization
Any condition that would make the participant, in the opinion of the investigator, unsuitable for the study
Participant will be reassessed prior to dosing to reconfirm eligibility criteria
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note